AstraZeneca to acquire Amolyt
14 March, 2024 AstraZeneca to acquire Amolyt Pharma,expanding late-stage rare disease pipeline Amolyt development portfolio includes Phase III asset with potential to address significant unmet need in patients with chronic hypoparathyroidism Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition, building on company's success in bone metabolism and opportunity in rare endocrinology AstraZeneca announced that it has entered into a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on